Balchem Corp

BCPC | NASDAQ

Price Alert Chart Builder DCF Calculator

$167.09

+$0.04 (+0.02%)

Sep 21, 2026, 11:01 AM ET · Market open

Overview Rating Statistics Financials Earnings Analysts Ownership Dividends Profile

+0.02%

(1D)

Rating

Updated: Aug 27, 2026

52.8

Fundamentals Average

Market Sentiment Bullish

Moat Narrow

Full Analysis

Key Statistics

Market Data

Market Cap $5.37B

1D Range

166.19 167.98

52W Range

139.17 183.90

Valuation (TTM)

PE 32.88

PB 4.12

EV/EBITDA 21.52

Valuation (NTM)

Forward PE 29.24

Forward PEG 7.78

Price Target $215

Cash Flow

FCF Yield 3.5%

SBC Adj. FCF Yield 3.1%

SBC Impact -10.4%

Margins

Gross Margin 36.3%

Operating Margin 21.1%

FCF Margin 17.4%

Growth (CAGR)

Revenue 3Y | 5Y 4.9% | 7.9%

Dil EPS 3Y | 5Y 18.3% | 13.0%

FCF 3Y | 5Y 21.3% | 8.5%

Returns

ROA 9.8%

ROE 12.8%

ROIC 11.5%

Financial Health

Net Debt

$92.21M

Current Ratio 2.66

Interest Coverage 25.29

Dividends

Div Yield 0.57%

Payout Ratio 18.9%

FCF Payout Ratio 16.3%

All Key Statistics

Loading financial charts...

Profile

Balchem Corporation develops, manufactures, and distributes specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant...

Sector Basic Materials

Industry Chemicals - Specialty

Employees 1,379

IPO Date Jun 2, 1986

Website www.balchem.com

Fiscal Year January - December

Full Company Profile

Latest News

12 days ago · globenewswire.com

Balchem Corporation to Participate in the 9th Annual Wells Fargo Consumer Conference on September 23, 2026

MONTVALE, N.J., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ: BCPC), a global specialty ingredient manufacturer for health and nutrition markets, announced they will participate in the 9th Annual Wells Fargo Consumer Conference on September 23, 2026.

2 months ago · seekingalpha.com

Balchem Corporation (BCPC) Q2 2026 Earnings Call Transcript

2 months ago · globenewswire.com

Balchem Corporation Reports Second Quarter 2026 Financial Results

MONTVALE, N.J., July 31, 2026 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ: BCPC) today reported financial results for its 2026 fiscal second quarter ended June 30, 2026.

2 months ago · globenewswire.com

Balchem Corporation Announces Quarterly Conference Call for Second Quarter 2026 Financial Results on July 31, 2026

MONTVALE, N.J., July 17, 2026 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ: BCPC) today announced that a conference call will be held on Friday, July 31, 2026, at 11:00 AM Eastern Time (ET) to review second quarter results.

3 months ago · globenewswire.com

Balchem Corporation to Participate in the CJS Securities 26th Annual New Ideas Summer Conference on July 9, 2026

MONTVALE, N.J., June 26, 2026 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ: BCPC), a global specialty ingredient manufacturer for health and nutrition markets, announced they will participate in the CJS Securities 26th Annual New Ideas Summer Conference on July 9, 2026.

4 months ago · globenewswire.com

Balchem Corporation to Participate in the Wells Fargo Industrials Conference on June 10, 2026

MONTVALE, N.J., May 27, 2026 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ: BCPC), a global specialty ingredient manufacturer for health and nutrition markets, announced they will participate in the Wells Fargo Industrials Conference on June 10, 2026.

5 months ago · seekingalpha.com

Balchem Corporation (BCPC) Q1 2026 Earnings Call Transcript

5 months ago · globenewswire.com

Balchem Corporation Reports First Quarter 2026 Financial Results

MONTVALE, N.J., April 30, 2026 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ: BCPC) reported today financial results for its 2026 fiscal first quarter ended March 31, 2026.

5 months ago · seekingalpha.com

Conestoga Capital SMid Cap Composite Q1 2026 Portfolio Holdings

The Conestoga SMid Cap Composite returned -10.24% net-of-fees in the first quarter, lagging the Russell 2500 Growth Index's return of -3.52%. RBC's performance was driven by continued strength in aerospace and defense, where demand remains robust and increasingly visible through a growing backlog. Despite a solid quarter, Repligen stock underperformed as investors focused on a more measured outlook and lingering concerns around end-market demand.